38169-97-0 Usage
Description
2-hydroxy-6-iodobenzaldehyde is a chemical compound with the molecular formula C7H5IO2. It is a derivative of benzaldehyde with a hydroxyl group at the 2-position and an iodine atom at the 6-position.
Used in Pharmaceutical Industry:
2-hydroxy-6-iodobenzaldehyde is used as a building block for the synthesis of various pharmaceuticals due to its versatile chemical properties.
Used in Agrochemical Industry:
2-hydroxy-6-iodobenzaldehyde is used as a building block for the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural chemicals.
Used in Organic Synthesis:
2-hydroxy-6-iodobenzaldehyde is used as a reagent in various chemical reactions, such as the synthesis of heterocycles and complex organic molecules, due to its unique structure and reactivity.
Used in Medicinal Chemistry Research:
2-hydroxy-6-iodobenzaldehyde is used in the investigation of its potential biological and pharmacological activities, making it an important compound for advancing knowledge in medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 38169-97-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,1,6 and 9 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 38169-97:
(7*3)+(6*8)+(5*1)+(4*6)+(3*9)+(2*9)+(1*7)=150
150 % 10 = 0
So 38169-97-0 is a valid CAS Registry Number.
38169-97-0Relevant articles and documents
INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE - SYNTHESIS AND USE THEREOF FOR TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA
-
Page/Page column 26-27, (2021/05/07)
The present invention relates to new compounds of general formula I, their synthesis, their pharmaceutically acceptable salts, and their use in treatment of T-cell acute lymphoblastic leukemia and lymphoma.
ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS
-
Page/Page column 89-90, (2010/06/15)
One object of the instant invention is to provide novel cholesterol absorption inhibitors of Formula I or pharmaceutically acceptable salts thereof.
